An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

Trial Profile

An Open Label, Roll Over Study to Provide Idelalisib to Subjects Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Idelalisib (Primary)
  • Indications Lymphoma
  • Focus Adverse reactions
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 18 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 06 May 2016 Status changed from not yet recruiting to recruiting.
    • 18 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top